Insights

Identifying Mutational Status in CLL
July 11, 2018 – 
Javier Pinilla-Ibarz, MD, PhD, discusses how to determine the mutational status of a patient with chronic lymphocytic leukemia and the significance of the chromosomal aberrations.
Diagnosing Chronic Lymphocytic Leukemia
July 11, 2018 – 
Javier Pinilla-Ibarz, MD, PhD, reviews the disease background of chronic lymphocytic leukemia and how it is diagnosed.
Ovarian Cancer: Coverage of PARP Inhibitors
January 09, 2018 – 
John L. Fox, MD, discusses current coverage considerations surrounding the use of PARP inhibitors for patients with advanced ovarian cancer.
Consulting With Gynecologic Oncologists for Input
January 09, 2018 – 
John L. Fox, MD, explains how collaboration between payers and gynecologic oncologists, as well as other specialists, can be valuable in improving the management of ovarian cancer.
Guidance for Payer Decisions in Ovarian Cancer
January 02, 2018 – 
John L. Fox, MD, provides an overview of current treatment guidelines in ovarian cancer and explains how they influence coverage decisions by payers.
Management Challenges in Ovarian Cancer
January 02, 2018 – 
John L. Fox, MD, remarks on unmet needs in the detection and management of ovarian cancer.
Patient Selection and PARP Inhibitors in Ovarian Cancer
December 27, 2017 – 
Robert L. Coleman, MD, discusses nuances in PARP inhibitor patient selection and explains how the research findings with these new drugs continues to move the ovarian cancer field forward.
Predictive Markers in Ovarian Cancer
December 19, 2017 – 
Robert L. Coleman, MD, offers insight regarding the current knowledge with predictive markers in ovarian cancer.
Ovarian Cancer: Practical Considerations in Maintenance
December 19, 2017 – 
Robert L. Coleman, MD, reviews evidence with bevacizumab in the frontline setting of ovarian cancer and discusses how the availability of newer options impacts maintenance decisions.
Efficacy and Safety of Rucaparib: A Focus on ARIEL3
December 12, 2017 – 
Robert L. Coleman, MD, offers insight regarding the findings from ARIEL3, with rucaparib in the switch maintenance setting of ovarian cancer.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!